Published in Emerg Infect Dis on October 01, 2002
Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis (2002) 5.23
Syndromic surveillance and bioterrorism-related epidemics. Emerg Infect Dis (2003) 3.00
Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis (2002) 2.76
Global transport networks and infectious disease spread. Adv Parasitol (2006) 2.20
Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg Infect Dis (2002) 1.59
Evaluation of a macrofoam swab protocol for the recovery of Bacillus anthracis spores from a steel surface. Appl Environ Microbiol (2006) 1.56
Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response. Emerg Infect Dis (2002) 1.53
Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother (2003) 1.53
Public health in the time of bioterrorism. Emerg Infect Dis (2002) 1.46
Discernment between deliberate and natural infectious disease outbreaks. Epidemiol Infect (2006) 1.44
Persistence of category A select agents in the environment. Appl Environ Microbiol (2007) 1.35
In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect Immun (2007) 1.33
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol Mol Biol Rev (2004) 1.28
Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin Diagn Lab Immunol (2004) 1.21
Airborne infection with Bacillus anthracis--from mills to mail. Emerg Infect Dis (2004) 1.16
In their own words: lessons learned from those exposed to anthrax. Am J Public Health (2005) 1.12
Inhalational anthrax (Ames aerosol) in naïve and vaccinated New Zealand rabbits: characterizing the spread of bacteria from lung deposition to bacteremia. Front Cell Infect Microbiol (2012) 0.92
Antibody responses to a spore carbohydrate antigen as a marker of nonfatal inhalation anthrax in rhesus macaques. Clin Vaccine Immunol (2011) 0.82
Interferon protects mice against inhalation anthrax. J Interferon Cytokine Res (2008) 0.81
Injectional anthrax infection due to heroin use induces strong immunological memory. J Infect (2014) 0.81
Antimicrobial Treatment for Systemic Anthrax: Analysis of Cases from 1945 to 2014 Identified Through a Systematic Literature Review. Health Secur (2015) 0.81
Multigeneration cross contamination of mail with Bacillus species spores by tumbling. Appl Environ Microbiol (2010) 0.80
Facilitation of risk communication during the anthrax attacks of 2001: the organizational backstory. Am J Public Health (2007) 0.78
Multigeneration Cross-Contamination of Mail with Bacillus anthracis Spores. PLoS One (2016) 0.75
Whole genome protein microarrays for serum profiling of immunodominant antigens of Bacillus anthracis. Front Microbiol (2015) 0.75
Bacillus spores in the mail: "ironing" out the anthrax problem. J Med Toxicol (2006) 0.75
Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis (2001) 11.73
The Sverdlovsk anthrax outbreak of 1979. Science (1994) 10.29
Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep (2001) 6.49
Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep (2001) 4.95
Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep (2001) 3.53
An epidemic of inhalation anthrax: the first in the twentieth century. II. Epidemiology. Am J Hyg (1960) 3.09
Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) (1956) 2.77
Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis (2002) 2.76
An epidemic of inhalation anthrax, the first in the twentieth century: I. Clinical features. 1960. Am J Med (2002) 1.86
Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response. Emerg Infect Dis (2002) 1.53
Bacillus anthracis aerosolization associated with a contaminated mail sorting machine. Emerg Infect Dis (2002) 1.52
Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay. J Infect Dis (1989) 1.43
Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis. Am J Trop Med Hyg (1984) 1.15
Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protective antigen (PA): measurement of human anti-PA antibodies. Clin Diagn Lab Immunol (1994) 1.11
Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis (2002) 1.04
Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med (2009) 16.13
Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med (2003) 15.48
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Public health assessment of potential biological terrorism agents. Emerg Infect Dis (2002) 8.49
Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med (2006) 7.68
Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep (2002) 6.51
Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis (2007) 6.41
Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA (2008) 6.13
Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA (2010) 5.94
Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA (2009) 5.84
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet (2006) 5.56
Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis (2002) 5.23
A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med (2002) 4.88
Neurologic manifestations and outcome of West Nile virus infection. JAMA (2003) 4.61
Operational research in low-income countries: what, why, and how? Lancet Infect Dis (2009) 4.56
Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis (2002) 4.08
Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis (2003) 4.02
Automatic electronic laboratory-based reporting of notifiable infectious diseases at a large health system. Emerg Infect Dis (2002) 3.88
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis (2011) 3.46
An outbreak of Rift Valley fever in Northeastern Kenya, 1997-98. Emerg Infect Dis (2002) 3.36
An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med (2003) 3.32
Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis (2009) 3.09
The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis (2003) 3.04
Bacterial meningitis in the United States, 1998-2007. N Engl J Med (2011) 2.99
Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. J Cataract Refract Surg (2012) 2.95
Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg Infect Dis (2002) 2.89
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J (2013) 2.80
Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis (2002) 2.76
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med (2011) 2.72
Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med (2005) 2.62
Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS One (2010) 2.59
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Acute flaccid paralysis and West Nile virus infection. Emerg Infect Dis (2003) 2.34
Real-time PCR assays for detection of bocavirus in human specimens. J Clin Microbiol (2006) 2.29
Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr Infect Dis J (2010) 2.29
Seasonal patterns of invasive pneumococcal disease. Emerg Infect Dis (2003) 2.29
Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med (2009) 2.25
Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother (2002) 2.20
Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci Transl Med (2012) 2.17
Superspreading SARS events, Beijing, 2003. Emerg Infect Dis (2004) 2.03
Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis (2005) 2.03
Bed net ownership in Kenya: the impact of 3.4 million free bed nets. Malar J (2010) 2.01
Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep (2015) 2.01
First confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in the United States, updated information on the epidemiology of MERS-CoV infection, and guidance for the public, clinicians, and public health authorities - May 2014. MMWR Morb Mortal Wkly Rep (2014) 2.00
Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol (2005) 2.00
Global perspectives for prevention of infectious diseases associated with mass gatherings. Lancet Infect Dis (2012) 1.99
Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. Lancet (2009) 1.95
Human coronavirus infections in rural Thailand: a comprehensive study using real-time reverse-transcription polymerase chain reaction assays. J Infect Dis (2007) 1.94
Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis (2011) 1.94
Threat of a biological terrorist attack on the US food supply: the CDC perspective. Lancet (2002) 1.85
Influenza in outpatient ILI case-patients in national hospital-based surveillance, Bangladesh, 2007-2008. PLoS One (2009) 1.85
Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine (2007) 1.85
Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One (2007) 1.84
Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep (2010) 1.79
Environment or host?: A case-control study of risk factors for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med (2012) 1.78
Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med (2013) 1.78
Hantavirus pulmonary syndrome--United States: updated recommendations for risk reduction. Centers for Disease Control and Prevention. MMWR Recomm Rep (2002) 1.77
Impact of maternal influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants. Arch Pediatr Adolesc Med (2006) 1.75
Incidence of influenza-like illness and severe acute respiratory infection during three influenza seasons in Bangladesh, 2008-2010. Bull World Health Organ (2011) 1.74
Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. J Infect Dis (2005) 1.72
Perinatal infections due to group B streptococci. Obstet Gynecol (2004) 1.69
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther (2012) 1.68
Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis (2005) 1.68
Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med (2006) 1.67
Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol (2004) 1.66
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis (2011) 1.66
Household transmission of pandemic (H1N1) 2009, San Antonio, Texas, USA, April-May 2009. Emerg Infect Dis (2010) 1.64
The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis (2005) 1.64
Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods (2008) 1.64
Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol (2011) 1.62
Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis (2012) 1.62
One-year health assessment of adult survivors of Bacillus anthracis infection. JAMA (2004) 1.61
An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001. J Infect Dis (2005) 1.60
Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg Infect Dis (2002) 1.59
Disease surveillance and the academic, clinical, and public health communities. Emerg Infect Dis (2003) 1.58
Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis (2004) 1.57
Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS (2006) 1.55
Potential influence of climate change on vector-borne and zoonotic diseases: a review and proposed research plan. Environ Health Perspect (2010) 1.53
Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response. Emerg Infect Dis (2002) 1.53
Population-based surveillance for postpartum invasive group a streptococcus infections, 1995-2000. Clin Infect Dis (2002) 1.53
Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis (2004) 1.51